AIAI Holdings' MediGuide Launches Precision Healthcare Solution With AI-Driven Diagnostics

AIAI Holdings' MediGuide Enters the State-of-the-Art Medicine Market With AI-Driven Innovation

Leveraging Advanced Diagnostics and Screenings to Provide Personalized Proactive Care DALLAS, July 14, 2026 (Newswire.com) - AIAI Holdings Corporation (NASDAQ:AIAI) ("Ai" or the "Company"), an AI-enabled diversified holding company utilizing Transformational AI (TAI) to enhance portfolio performance, today announced that its portfolio company, MediGuide, has launched a state of the art (SOTA) precision healthcare solution that combines advanced medical intelligence, expert clinical review, and AI-enabled diagnostic support to enable more personalized, data-driven medical decision-making. The launch represents another milestone in MediGuide's innovation roadmap and reflects AIAI Holdings' strategy of supporting portfolio companies that responsibly integrate advanced technologies into scalable, real-world business applications. "Every patient is different, yet too many healthcare decisions are still guided by generalized treatment approaches. We believe people deserve care that's informed by their unique biology, medical history, and individual health needs," said Vera Guerreiro, Chief Executive Officer of MediGuide. "Our precision healthcare solution brings together advanced medical intelligence, expert clinical review, and AI-enabled insights to help make that level of personalized care more accessible." "One of AIAI Holdings' core objectives is to partner with exceptional management teams that are building innovative, technology-enabled businesses capable of creating long-term shareholder value," commented Todd Furniss, Chief Executive Officer and Co-Founder of AIAI Holdings. "MediGuide's latest state of the art healthcare offering is an excellent example of that strategy in action. By combining artificial intelligence with world-class clinical expertise, MediGuide continues to strengthen its position in one of healthcare's fastest-growing markets while advancing solutions designed to improve patient outcomes." The new offering builds upon MediGuide's established Medical Second Opinion (MSO) services by combining genetic, molecular, clinical, and lifestyle information with AI-enabled analytics and expert physician review. This integrated approach helps improve diagnostic confidence, supports earlier detection, and enables more personalized treatment recommendations tailored to each patient's unique clinical profile. Key capabilities of the new offering will include: Comprehensive Diagnostics: Integrating genetic, molecular, and clinical information to provide a more complete and individualized understanding of each patient's condition. TAI-Enabled Clinical Insights: Leveraging artificial intelligence and machine learning to support clinical decision making and provide physicians with actionable insights that support diagnostic accuracy and clinical decision making. Personalized Treatment Guidance: Supporting healthcare providers in identifying treatment approaches that are better aligned with each patient's unique biological profile, moving beyond traditional one-size-fits-all care. Earlier Detection and Personalized Proactive Care: Focusing on identifying potential health risks sooner, improving diagnostic confidence, and helping patients and physicians make more informed healthcare decisions. The launch comes as insurers and reinsurers face rising claims tied to specialist referrals, increasing demand for international partners that can provide clinical review and evidence-based recommendations rather than reports alone.Learn more at MediGuide: www.mediguide.com. About AIAI Holdings Corporation AIAI Holdings Corporation (Ai) (NASDAQ:AIAI) is an AI-enabled diversified holding company that acquires and grows companies across multiple industries. We expect to drive revenue and earnings growth throughout our portfolio by applying exclusively licensed Transformational AI to enhance operational efficiency and financial performance. Ai is building a next-generation model for technology-enabled business operations, which is expected to create sustainable value for shareholders through the strategic integration of artificial intelligence across diverse industries. About MediGuide MediGuide is a global medical intelligence company dedicated to helping individuals make informed healthcare decisions when they matter most. Founded in 1999, the Company provides Medical Second Opinions, Medical Treatment Abroad, Digital Health, and Preventive Health solutions through an integrated healthcare platform that connects members with world-renowned medical centers and leading specialists around the globe. Operating across more than 160 countries with a network spanning five continents, MediGuide partners with insurers, employers, financial institutions, and healthcare organizations to deliver expert clinical guidance, personalized care navigation, and innovative digital health services. By combining world-class medical expertise with advanced technology and AI-enabled healthcare solutions, MediGuide empowers patients with greater confidence, improved clinical outcomes, and access to the highest standards of care worldwide. Learn more at MediGuide. MediGuide is a portfolio company of AIAI Holdings Corporation (NASDAQ:AIAI). Cautionary Note Regarding Forward Looking Statements This press release contains "forward-looking statements" or "forward-looking information" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the plans, intentions, beliefs, and current expectations of the Company with respect to future business activities and plans of the Company. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations, intentions, beliefs, plans, objectives, goals, strategies, future events or performance, and underlying assumptions. Forward-looking statements are often identified by the use of words such as "may," "will," "expect," "believe," "anticipate," "intend," "would," "could," "should", "estimate," "plan," "predict," "project," "estimate", or "continue," or similar expressions, including the negative of these terms or other comparable terminology. Forward-looking statements are based on the Company's current expectations regarding its strategy, plans, intentions, performance, or future occurrences or results, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of known and unknown risks, uncertainties, and other factors, many of which are outside of the Company's control, that could cause actual results, performance, or achievements to materially differ from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks, uncertainties and other factors include, but are not limited to our lack of operating history, our ability to attract new investments, our failure to manage growth effectively, our acquisition activities may pose risks that could harm our business, and our licensed AI may not perform up to the expected standards, as well as general business and economic conditions, competitive pressures, regulatory changes, technological developments, and other factors identified in the Company's most recent filings with the U.S. Securities and Exchange Commission, including our Registration Statement on Form S-1, which are available for review at www.sec.gov. Furthermore, the Company operates in a competitive environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any intention to, and, except as may be required by law, undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which the Company hereafter become aware. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Investor Relations Matthew Selinger, Senior Partner Integrous Communications Email: [email protected] Phone: 415-572-8152 Visit and follow AIAI Holdings Corporation online: Website: www.aiaiholdings.com LinkedIn: https://www.linkedin.com/company/aiaiholdings/ X/Twitter: https://x.com/_AiSquared Instagram: https://www.instagram.com/_aisquared/ Facebook: https://www.facebook.com/aiaiholdings

AIAI portfolio company MediGuide launches precision healthcare service By Investing.com

DALLAS - AIAI Holdings Corporation (NASDAQ:AIAI) announced today that its portfolio company MediGuide has launched a precision healthcare solution combining medical intelligence, clinical review, and AI-enabled diagnostic support, according to a press release statement. The announcement comes as AIAI shares trade at $10.14, near their 52-week low of $9.86, with the stock down 20% over the past week. According to InvestingPro analysis, the company appears overvalued relative to its Fair Value, with shares showing high volatility. The company, valued at $709 million, remains unprofitable over the last twelve months. The service integrates genetic, molecular, clinical, and lifestyle information with AI-enabled analytics and expert physician review. The offering builds upon MediGuide's existing Medical Second Opinion services. "Every patient is different, yet too many healthcare decisions are still guided by generalized treatment approaches," said Vera Guerreiro, Chief Executive Officer of MediGuide. The new offering includes comprehensive diagnostics that integrate genetic, molecular, and clinical information, AI-enabled clinical insights using artificial intelligence and machine learning, personalized treatment guidance for healthcare providers, and earlier detection capabilities. Todd Furniss, Chief Executive Officer and Co-Founder of AIAI Holdings, said the launch represents the company's strategy of partnering with management teams building technology-enabled businesses. MediGuide, founded in 1999, provides medical second opinions, medical treatment abroad, digital health, and preventive health solutions. The company operates across more than 160 countries with a network spanning five continents, partnering with insurers, employers, financial institutions, and healthcare organizations. AIAI Holdings Corporation is an AI-enabled diversified holding company that acquires and grows companies across multiple industries. The company applies licensed artificial intelligence technology to enhance operational efficiency and financial performance across its portfolio. In other recent news, NetraMark Holdings Inc. has secured its first contract through a contract research organization (CRO) partnership to analyze a phase 2 neurodegeneration dataset. This agreement signifies a shift for NetraMark, as it is their first contract obtained via a CRO instead of directly with a biopharmaceutical company. The company will utilize its NetraAI platform to assess trial data, aiming to identify Model-Derived Subgroups and treatment-response patterns. Additionally, AIAI Holdings Corporation announced the launch of a new enterprise digital platform by its portfolio company, MediGuide International. The platform is designed to integrate with insurers, payors, and digital health partners, offering services such as Medical Second Opinion and virtual care through a single integration. Furthermore, AIAI Holdings Corporation has introduced the Arca Wallet, a self-custodial mobile application for managing digital dollars. Developed by Constellation Network, the wallet allows users to manage digital dollars without needing a bank account and is available on major app stores. These developments highlight the companies' ongoing efforts to innovate and expand their service offerings. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.